Swiss drugmaker unveils promising data for obesity drug
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Independent experts conclude unanimously that the experimental treatment is effective
US drugmaker races to scale up ingredient production to meet demand for Mounjaro and Zepbound jabs
Shares of world’s most valuable pharmaceuticals group reapproach record highs
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
Ecommerce giant says it stands to generate ‘a lot of revenue’ from Eli Lilly’s Zepbound and similar treatments
Eli Lilly and Novo Nordisk’s weight-loss drugs have transformed their fortunes but a backlash could be looming
Retail group agrees first partnership with a big drug company since launching online pharmacy business in 2020
Breakthrough medicine will now be subject to further review by committee of independent experts
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
US group relies on some of the sites being purchased by competitor to produce its own treatments
Mounjaro has achieved 22.5 per cent loss of body weight in trials
Danish biotech group Zealand Pharma is developing an alternative obesity treatment to compete with big rivals
The clamour for anti-obesity drugs has sent the pharma group’s shares on an epic run
US and UK regulators say diabetes medication showed ‘significant’ weight loss benefits
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
Cheaper valuations have finally drawn back cash-rich pharmaceutical makers
Point is developing radioligand molecules that can deliver targeted radiation to tumour cells
BNP Paribas joins environmentalists in pressing companies to run toxin tests with synthetic substances
Low-cost domestic rivals hope to challenge Novo Nordisk in one of world’s biggest markets for anti-obesity medication
